Nevirapine is better than efavirenz at raising good cholesterol
Two of the most commonly prescribed drugs for treating HIV (antiretroviral drugs)--nevirapine and efavirenz--can both raise levels of the "good type" of cholesterol (HDL cholesterol), but nevirapine raises it higher than efavirenz, according to a new study by van Leth and colleagues published in the launch issue of PLoS Medicine. "These data suggest that nevirapine may be preferable to efavirenz in HIV-infected adults who have increased cardiovascular risk," says Andrew Carr, an HIV specialist at St. Vincents Hospital in Sydney, Australia, who was not involved in the study. Cardiovascular risk factors include high blood pressure, diabetes, and smoking, which put patients at higher risk of heart disease and stroke.
However, perceived cardiovascular risk is only one factor that would affect the choice between these two drugs, notes Carr. Efavirenz is thought to be marginally better than nevirapine at keeping HIV infection under control; efavirenz is also advantageous because patients only need to take it once a day, whereas nevirapine must be taken twice daily. The new study "moves clinicians and patients away from one-size-fits-all antiretroviral therapy," says Carr, allowing them to weigh up the different advantages and disadvantages of each drug.
In the study, the researchers compared the cholesterol levels in 417 patients with HIV who were taking nevirapine against 289 patients who were taking efavirenz. None of the patients had been on any antiretroviral drugs before. Patients taking nevirapine had a significantly larger increase in HDL cholesterol compared with patients taking efavirenz.
Although the increase was higher with nevirapine, this does not prove that nevirapine is better at reducing the risk of heart disease and strokes, says Carr. The researchers did not look at the risk of these diseases in their study.
Praphan Phanuphak, of the Thai Red Cross AIDS Research Center in Bangkok, Thailand, who was one of the authors of the study, says that the findings are particularly important for treating HIV in the developing world. "Nevirapine is much cheaper, particularly in developing countries where generic drugs are available," says Phanupak. "In many developing countries, nevirapine is incorporated in fixed dose combination with other drugs such as stavudine and lamivudine which costs only US$1 per day."
Paul Ocampo | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Mapping the interaction of a single atom with a single photon may inform design of quantum devices
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...